CE Mark for Vagus Nerve Stimulation Therapy from Liva Nova to treat epilepsy.

LivaNova PLC announced it received CE Mark for its Vagus Nerve Stimulation Therapy (�VNS Therapy�) System comprised of the SenTiva generator and next-generation Programming System for the treatment of patients with drug-resistant epilepsy. The Company received FDA approval for the full VNS Therapy System in October 2017.

The SenTiva generator offers the smallest and lightest responsive therapy with a number of new advanced features for the treatment of DRE. SenTiva is the only device of its size to include the AutoStim Mode, also known as Seizure Response Mode, which is designed to detect seizures and automatically deliver an extra dose of therapy. The generator is also designed to collect and log events including a patient�s body position and heart rate fluctuations. The next-generation Programming System includes a small tablet and wireless programming wand compatible with the SenTiva generator and all LivaNova legacy VNS Therapy generators. When combined with SenTiva�s smart technology, the Programming System provides several advanced options and makes delivering treatment easier and more efficient through personalized patient-centric features.

Edward Andrle, LivaNova�s General Manager of its Neuromodulation business franchise stated �Not only is the new VNS Therapy System simpler to use, making drug-resistant epilepsy treatment easier, the SenTiva generator and Programming System work together to allow physicians to confidently deliver proven results through customizable, smart technology. After a successful launch in the U.S., we look forward to seeing European patients benefit from our latest technology advancements.�